All of the active B12 group reporting showed reduction in severity of symptoms ranging from 31% to 70%, while the placebo controls reported either no change or a worsening of symptoms. Wilcoxon-Rank of .002 for the end-points of sneezing, nasal congestion and runny nose; and p urinarytractinfections = .005 for IgE reductions. In 1992, the above mentioned urinarytractinfections data from 1988 on were presented by Dr. O''Connor to the FDA. The FDA panel acknowledged the safety of the treatment. The panel seemed to be in agreement that the statistics indicated a significant reduction in IgE and that a quantitative drop in symptoms was demonstrated. In 1992, Belen Anibarro, MD, studied five children with asthma with metabisulfite intolerance confirmed by oral challenge testing. The test was repeated after premedication with 1.5 mg of oral cyanocobalamin. In four of urinarytractinfections the five patients treated, bronchospasm did not develop in the second metabisulfite challenge.6

A recent study in Japan indicates that B12 treatment helps in the growth and division of certain immune system cells.11 These cells urinarytractinfections and urinarytractinfections function to prevent the immune system from over-reacting to allergens such as animals, mold, dust, and pollen. They are called suppressor cells or CD8+ lymphocytes. urinarytractinfections They “put the brakes on the immune system”. this medicationTM is a 21-day treatment of B12 lozenges sucked on twice daily. this medicationTM may help patients urinarytractinfections with hay urinarytractinfections fever by providing urinarytractinfections the patient’s suppressor cells with the sustained and elevated blood B12 level they need to grow and divide. urinarytractinfections It appears that by helping the immune system to become what it is genetically capable of becoming, this medicationTM turns at least some allergic people into non-allergic or moderately-allergic people.